RXi Pharmaceuticals Corp Stock Nasdaq
Equities
US74979C3034
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-21 | Phio Pharmaceuticals Files $100 Million Mixed Shelf | MT |
05-15 | Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study | MT |
Sales 2024 * | - | Sales 2025 * | 75M 102M | Capitalization | 3.51M 4.8M |
---|---|---|---|---|---|
Net income 2024 * | -9M -12.29M | Net income 2025 * | 47M 64.18M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
0.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |